BAY u3405 is a potent and competitive antagonist of U46619, PGD2 and 9 alpha, 11 beta PGF2 alpha-induced contractions of airway smooth muscle.
Norman
P
P
Bayer UK, Ltd., Research Department, Slough, England.
Cuthbert
N J
NJ
Gardiner
P J
PJ
McKenniff
M G
MG
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D000818:Animals; D002227:Carbazoles / Q000494:pharmacology*; D015237:Dinoprost / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006168:Guinea Pigs; D066298:In Vitro Techniques; D009119:Muscle Contraction / Q000187:drug effects*; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology*; D015230:Prostaglandin D2 / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D011450:Prostaglandin Endoperoxides, Synthetic / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*; D013931:Thromboxanes / Q000037:antagonists & inhibitors*; D014132:Trachea / Q000187:drug effects / Q000502:physiology*
D002227:Carbazoles; D011450:Prostaglandin Endoperoxides, Synthetic; D013449:Sulfonamides; D013931:Thromboxanes; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D015237:Dinoprost; C063119:ramatroban; D015230:Prostaglandin D2